This Medical Device Stock Is Breaking Out Just Before Earnings

Signal: BUY | Score: 46.99/100

Establishment Labs (ESTA) is setting up for a momentum play heading into May earnings. The stock is oversold at $57, sitting 32% below its 52-week high of $83.31, while analysts maintain an aggressive $89 price target. With an RSI of 35 showing oversold conditions and a strong earnings beat last quarter, this medical device company is primed for a bounce.

The Setup

ESTA is showing classic oversold technicals with an RSI of 35.22, well below the 30 threshold that typically signals buying opportunities. The stock has pulled back significantly from its February highs but is holding above key support levels around $55. Volume patterns suggest institutional accumulation, and with 34 days until the next earnings report on May 6th, we're in the sweet spot for pre-earnings momentum building.

The Catalyst

The setup here revolves around ESTA's impressive earnings trajectory and upcoming Q1 2026 results. On February 24, 2026, the company crushed expectations with an EPS of -$0.09 versus the -$0.22 consensus, beating by $0.13 per share. This followed strong Q2 2025 performance where revenue jumped 16.1% year-over-year to $51.30 million, exceeding estimates. The company has shown consistent ability to surprise to the upside, and with analysts maintaining a "strong buy" rating and $89 target, expectations are building for another beat on May 6th.

Bull Case

• Earnings momentum: Two consecutive quarters of positive surprises suggest operational improvements are accelerating, with losses narrowing faster than expected • Revenue growth acceleration: 45.2% year-over-year revenue growth shows the medical device market is responding to ESTA's products • Massive upside potential: Current price of $57 versus analyst target of $89 represents 56% upside in a market that's hungry for growth stories

Bear Case

• High valuation metrics: Forward P/E of 278 and price-to-book of 70.9 leave little room for execution mistakes • Debt concerns: Debt-to-equity ratio of 1,123 creates financial risk if growth doesn't materialize as expected

The Trade

Entry: $57.00 (current level)
Target: $78.00 (37% upside toward analyst target)
Stop Loss: $52.00 (below recent support)
Risk/Reward: 1:4.2
Timeframe: 6-8 weeks (through earnings)

*This is one person's analysis, not financial advice. Always do your own research.*